How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

937 results for

Drug-induced Lupus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Detailed features of hematological involvement and medication-induced cytopenia in systemic lupus erythematosus patients: single center results of 221 patients Full Text available with Trip Pro

Detailed features of hematological involvement and medication-induced cytopenia in systemic lupus erythematosus patients: single center results of 221 patients Systemic lupus erythematosus (SLE) may affect a number of systems, with the hematological system being one of the most common. Our aim is to determine the existence of cytopenia at diagnosis or during follow-up of our SLE patients as well as the associated factors.A cohort of SLE patients that had been followed-up in the Department (...) was disease-related in 83.4% (n=166) and medication-related in 16.6% (n=33) of the patients. In cases of drug-induced cytopenia, azathioprine was the most frequently prescribed drug. In patients with cytopenia at the time of diagnosis, erythrocyte sedimentation rates (ESR) were higher, C3 and C4 hypocomplementemia was more prevalent, and they were positive for anti-ds-DNA at a greater proportion (p<0.001, p=0.015, p=0.028, and p=0.019, respectively). Moreover, photosensitivity, renal involvement

2017 European journal of rheumatology

3. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. (Abstract)

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Drug-induced lupus (DIL) is an idiosyncratic side effect of treatments in which symptoms overlap with those of systemic lupus erythematosus (SLE). The spectrum of DIL constantly evolves with that of the pharmacopoeia. Here, we used VigiBase, the WHO global individual case safety reports (ICSRs) database, to identify the main drugs associated with DIL.We analysed all ICSRs (...) classified as 'systemic lupus erythematosus' according to the Medical Dictionary for Drug Regulatory Activities term (preferred term level) in VigiBase. The drugs considered in the analysis were those not used to treat SLE, with a positive lower end of the 95% credibility interval for the information component (IC025) ≥0, an indicator value for disproportionate Bayesian reporting.A total of 12 166 DIL ICSRs were identified using VigiBase. From those, 8163 ICSRs reporting on 118 suspected drugs with IC025

2019 Annals of the Rheumatic Diseases

4. Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: An uncommon cause of drug-induced discoid lupus erythematosus. (Abstract)

Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: An uncommon cause of drug-induced discoid lupus erythematosus. Drug-induced chronic cutaneous lupus erythematosus, or drug-induced discoid lupus erythematosus, is a rare cutaneous phenomenon. Various medications have been associated with drug-induced discoid lupus erythematosus including fluorouracile agents, especially tegafur and uraciltegafur, and TNF-α antagonists such as infliximab (...) or etanercept. Recent literature has described a case series of six patients receiving IgG immunoglobulin for chronic inflammatory demyelinating polyneuropathy with subsequent presentations of discoid lupus erythematosus. We present a patient with chronic inflammatory demyelinating polyneuropathy who developed discoid lupus erythematosus secondary to IgG immunoglobulin.© 2019 The Australasian College of Dermatologists.

2019 Australasian Journal of Dermatology

5. Are there distinct clinical and pathological features distinguishing Idiopathic from Drug-Induced Subacute Cutaneous Lupus Erythematosus? A European retrospective multicenter study. (Abstract)

Are there distinct clinical and pathological features distinguishing Idiopathic from Drug-Induced Subacute Cutaneous Lupus Erythematosus? A European retrospective multicenter study. Clinical and pathological criteria to distinguish drug-induced subacute lupus erythematosus (DI-SCLE) from idiopathic (I-SCLE) are controversial.Aim of the survey was a retrospective analysis of a consistent number of iatrogenous and idiopathic SCLE cases, by means of clinical and histopathological

2019 Journal of American Academy of Dermatology

6. Stevens-Johnsons syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature Full Text available with Trip Pro

Stevens-Johnsons syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature Tumor necrosis factor inhibitors are the first biological agents used in the treatment of rheumatoid arthritis (RA) to have yielded satisfactory results in terms of clinical improvement and radiologic progression, but they are also associated with the possibility of occurrence of a number of autoimmune systemic events [drug-induced lupus (DIL), vasculitis, sarcoidosis] and localized (...) adverse events [uveitis, psoriasis, interstitial lung disease, erythema multiforme including the major form Stevens-Johnson syndrome (SJS)]. During treatment with TNF inhibitors, many patients develop positivity for antinuclear, antihistone and anti-double stranded DNA antibodies, though only a minority of patients will develop clinical manifestations and approximately less than 1% will fulfill the classification criteria for systemic lupus erythematosus. Mucocutaneous manifestations are the most

2018 Biomedical reports

7. Drug-induced lupus: Traditional and new concepts. (Abstract)

Drug-induced lupus: Traditional and new concepts. Drug-induced lupus (DIL) includes a spectrum of drug-induced reactions often characterised by a clinical phenotype similar to that of idiopathic systemic lupus eruthematosus (SLE) but usually lacking major SLE complications. Different drugs may be associated with distinct clinical and serological profiles, and early recognition is crucial. Drugs traditionally associated with DIL include procainamide, hydralazine, quinidine and others, but strong

2018 Autoimmunity reviews

8. Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis. (Abstract)

Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis. Hydralazine is an antihypertensive medication that has been associated with drug-induced lupus erythematosus (DIL) as well as ANCA-associated vasculitis (AAV). Although rare, early diagnosis is critical since drug cessation is the mainstay of therapy. This retrospective study aims to characterize the clinical, laboratory, and histopathologic features of this disease.Once approval was obtained from

2018 Seminars in arthritis and rheumatism

9. Drug-induced lupus erythematosus: an update on drugs and mechanisms. (Abstract)

Drug-induced lupus erythematosus: an update on drugs and mechanisms. Rapid introduction of newly developed drugs in the absence of clear understanding of the pathophysiologic mechanisms behind drug-induced lupus erythematosus (DILE) can sometimes make DILE difficult to recognize in clinical practice. The purpose of this review is to summarize drugs most recently reported to be involved in DILE and discuss the current landscape of diverse mechanisms involved.A large number of proton pump (...) results in improvement of drug-induced manifestations. Characterizing the mechanisms involved might help better understand the cause of idiopathic autoimmunity.

2018 Current Opinion in Rheumatology

10. Management of drug-induced immune and secondary autoimmune, haemolytic anaemia

, Manchester, 5 Barts and The London School of Medicine and Dentistry, London Correspondence: BSH Secretary, British Society for Haematology, 100 White Lion Street, London, N1 9PF e-mail bshguidelines@b-s-h.org.uk KEYWORDS Autoimmune haemolytic anaemia, drug induced immune haemolytic anaemia, Evans syndrome, cancer, infection, systemic lupus erythematosus, common variable immunodeficiency, ulcerative colitis, transplantation. 2 SCOPE The objective of this guideline is to provide healthcare professionals (...) Management of drug-induced immune and secondary autoimmune, haemolytic anaemia 1 Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia Quentin A Hill 1 , Robert Stamps 2 , Edwin Massey 3 , John D Grainger 4 , Drew Provan 5 and Anita Hill 1 on behalf of the British Society for Haematology. 1 Department of Haematology, Leeds Teaching Hospitals, 2 NHSBT, Sheffield, 3 NHSBT, Bristol, 4 Royal Manchester Children’s Hospital, University of Manchester

2016 British Committee for Standards in Haematology

11. Drug Induced Lupus Erythematous Secondary to Pirfenidone. (Abstract)

Drug Induced Lupus Erythematous Secondary to Pirfenidone. 29266198 2018 06 13 1365-2133 178 6 2018 Jun The British journal of dermatology Br. J. Dermatol. Drug-induced lupus erythematosus secondary to pirfenidone. 1437-1438 10.1111/bjd.16246 Kelly A S AS http://orcid.org/0000-0003-2244-3243 Dermatology Department, St. Vincent's University Hospital, Elm Park, Dublin 4, Dublin, Ireland. De la Harpe Golden P P Histopathology Department, St. Vincent's University Hospital, Elm Park Dublin 4, Dublin

2017 British Journal of Dermatology

12. Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands Full Text available with Trip Pro

Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands Subacute cutaneous lupus erythematosus (SCLE) is a well-defined subtype of lupus erythematosus, characterised by photosensitivity, annular and/or psoriasiform lesions, variable systemic involvement and presence of circulating SSA/anti-Ro antibodies. SCLE may be idiopathic or drug-induced. Both the idiopathic and drug-induced forms of SCLE are analogous in their clinical, serological and histological features. Drug (...) consistent with SCLE. We propose that our patient's unique presentation of SCLE may be explained by a prolonged occupational exposure to topical terbinafine as a foot masseuse. While oral terbinafine is a drug known to cause drug-induced SCLE, to our knowledge, this is the first topically induced form of the disease.

2017 Lupus science & medicine

13. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors Full Text available with Trip Pro

Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease that may be induced by proton pump inhibitors (PPIs) in at-risk populations. The US FDA does not recognize SCLE as an adverse event associated with PPIs. We queried the FDA Adverse Event Reporting System database, which contains adverse event case reports submitted by the public as well as by industry, and analyzed the data to quantify

2016 Drugs - real world outcomes

14. Drug-Induced Lupus Erythematosus Associated with Antiretroviral Therapy in a Patient with Human Immunodeficiency Virus: A Case Report Full Text available with Trip Pro

Drug-Induced Lupus Erythematosus Associated with Antiretroviral Therapy in a Patient with Human Immunodeficiency Virus: A Case Report Antiretroviral medications are the mainstay of human immunodeficiency virus (HIV) therapy and some have been in use for over 20 years. To date, there have been no reported cases of antiretroviral therapy (ART) induced drug-induced lupus erythematosus (DILE). We present a case of a 35-year-old woman who received a combination of emtricitabine, rilpivirine

2017 Cureus

15. Drug-induced Lupus

Drug-induced Lupus Drug-induced Lupus Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Drug-induced Lupus Drug-induced Lupus Aka: Drug (...) -induced Lupus , Drug Induced Lupus , Systemic Lupus Secondary to Medication , Medication Causes of Systemic Lupus Erythematosus II. Causes More than 80 drugs associated (first described in 1945 related to sulfadiazine) (most common cause) ( ) Ethosuximide s s III. Symptoms (following causative medication use) See s Rash Serositis Hematologic abnormalities IV. Labs Screening indicated for causative medication use and symptoms suggestive of SLE (see above) ANA Titer Confirmatory testing if positive ANA

2018 FP Notebook

16. Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report Full Text available with Trip Pro

Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report Rowell syndrome is defined as the association between lupus erythematosus, erythema multiforme-like lesions and characteristic immunological changes including positive tests for rheumatoid factor, speckled antinuclear antibody, positive anti-Ro or anti-La antibodies. The present report presents the case of a 45-year-old female patient who was previously diagnosed in January 2010 with terbinafine-induced subacute (...) -occurrence of subacute lupus erythematosus and Rowell syndrome lesions, which was drug-induced.

2017 Experimental and therapeutic medicine

17. Drug-Induced Acute Pancreatitis and Pseudoaneurysms: An Ominous Combination Full Text available with Trip Pro

Drug-Induced Acute Pancreatitis and Pseudoaneurysms: An Ominous Combination Rupture of pseudoaneurysms is rare but can be life-threatening complications of acute or chronic pancreatitis, usually due to enzymatic digestion of vessel walls crossing peripancreatic fluid collections. We report the case of a 40 year-old female, with multisystemic lupus and anticoagulated for prior thrombotic events, admitted for probable cyclosporine-induced acute pancreatitis. Hemodynamic instability occurred due

2016 GE Portuguese journal of gastroenterology

18. Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy Full Text available with Trip Pro

Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy Leflunomide is an immunomodulatory drug exhibiting anti-inflammatory, anti-proliferative and immunosuppressive effects. It has been widely used for treatment of active rheumatoid arthritis. Despite its good safety profile cutaneous side effects like alopecia, eczema, pruritis and dry skin have been reported with Leflunomide use. Skin ucleration, vasculitis, lichenoid drug rash and Subacute Cutaneous (...) Lupus Erythematosus (SCLE) have been rarely reported with its use. A rare case of Leflunomide induced SCLE is being reported in a female patient with rheumatoid arthritis. The clinical features, histopathological and immunological characteristics were consistent with drug induced SCLE. Withdrawal of Leflunomide along with short course of topical steroids resulted in resolution of symptoms suggesting the drug to be the culprit. As this drug comes into widespread use, it remains to be seen whether

2016 Journal of clinical and diagnostic research : JCDR

19. Drug-induced systemic lupus erythematosus in a child after 3 years of treatment with carbamazepine. (Abstract)

Drug-induced systemic lupus erythematosus in a child after 3 years of treatment with carbamazepine. Drug-induced lupus erythematosus (DILE) is a less severe variant of systemic lupus erythematosus (SLE) that generally resolves within weeks or months after the withdrawal of the implicated drug. DILE is unusual during childhood, with the most frequent age of presentation being at 50-70 years of age. Among different drugs, most commonly procainamide and hydralazine have been implicated as a cause (...) of DILE. However carbamazepine (CBZ) is considered a low-risk drug and very few cases have been reported in children. We describe the case of CBZ-induced SLE in a 9-year-old girl following 3 years of CBZ therapy. This case report shows that drug-induced SLE is an important side-effect to be considered, even after long-term treatment with CBZ, and also during childhood.© 2015 The Australasian College of Dermatologists.

2015 Australasian Journal of Dermatology

20. Drug-induced lupus erythematosus associated with donepezil: a case report. Full Text available with Trip Pro

Drug-induced lupus erythematosus associated with donepezil: a case report. The possibility that drug-induced lupus erythematosus (DILE) can be induced by donepezil is presented in this clinical case. Donepezil is an inhibitor of acetylcholinesterase used for the treatment of Alzheimer's disease. It is the first time that donepezil causes DILE. © The Author 2015. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email

2015 Age and ageing

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>